Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Palladini

Showing results (31-40 of 281) with videos related to

Pageof 29
Sort By:
Haematologica|July 2, 2019
Predicting survival in light chain amyloidosisGiovanni Palladini, Paolo Milani, Giampaolo Merlini
Clinical Chemistry and Laboratory Medicine|February 19, 2021
Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disordersFrancesca Lavatelli, Giovanni Palladini, Giampaolo Merlini
Expert Opinion on Drug Safety|February 15, 2021
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosisMario Nuvolone, Marco Basset, Giovanni Palladini
The New England Journal of Medicine|October 11, 2002
Hereditary amyloidosisGiovanni Palladini, Laura Obici, Giampaolo Merlini
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|July 29, 2016
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditionsPaolo Milani, Giovanni Palladini, Giampaolo Merlini
British Journal of Haematology|February 4, 2020
A powerful oral triplet for AL amyloidosisGiovanni Palladini, Paolo Milani, Giampaolo Merlini
Haematologica|November 21, 2007
Bortezomib in the treatment of AL amyloidosis: targeted therapy?Roberto Sitia, Giovanni Palladini, Giampaolo Merlini
Mediterranean Journal of Hematology and Infectious Diseases|March 14, 2018
Light Chain AmyloidosisPaolo Milani, Giampaolo Merlini, Giovanni Palladini
JACC. Cardiooncology|May 22, 2024
Learning From Trials: Time to Look More Closely at the Kidneys in ATTR Amyloidosis?Laura Obici, Roberta Mussinelli, Giovanni Palladini
Blood|December 3, 2020
Management of AL amyloidosis in 2020Giovanni Palladini, Paolo Milani, Giampaolo Merlini
Pageof 29

Showing results (31-40 of 281) with videos related to

Sort By:
Pageof 29
Haematologica|July 2, 2019
Predicting survival in light chain amyloidosisGiovanni Palladini, Paolo Milani, Giampaolo Merlini
Clinical Chemistry and Laboratory Medicine|February 19, 2021
Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disordersFrancesca Lavatelli, Giovanni Palladini, Giampaolo Merlini
Expert Opinion on Drug Safety|February 15, 2021
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosisMario Nuvolone, Marco Basset, Giovanni Palladini
The New England Journal of Medicine|October 11, 2002
Hereditary amyloidosisGiovanni Palladini, Laura Obici, Giampaolo Merlini
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|July 29, 2016
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditionsPaolo Milani, Giovanni Palladini, Giampaolo Merlini
British Journal of Haematology|February 4, 2020
A powerful oral triplet for AL amyloidosisGiovanni Palladini, Paolo Milani, Giampaolo Merlini
Haematologica|November 21, 2007
Bortezomib in the treatment of AL amyloidosis: targeted therapy?Roberto Sitia, Giovanni Palladini, Giampaolo Merlini
Mediterranean Journal of Hematology and Infectious Diseases|March 14, 2018
Light Chain AmyloidosisPaolo Milani, Giampaolo Merlini, Giovanni Palladini
JACC. Cardiooncology|May 22, 2024
Learning From Trials: Time to Look More Closely at the Kidneys in ATTR Amyloidosis?Laura Obici, Roberta Mussinelli, Giovanni Palladini
Blood|December 3, 2020
Management of AL amyloidosis in 2020Giovanni Palladini, Paolo Milani, Giampaolo Merlini
Pageof 29